The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.

A new report has revealed that 83% of life sciences CEOs view Internet of Medical Things (IoMT) devices as the most important ...

The lack of initial public offerings (IPOs) also reflects a year of restricted growth. As per the BIA, no UK biotechs went ...

The UK's NICE now recommends the NHS use of Pfizer's daily prostate cancer pill, Talzenna alongside hormone therapy Xtandi.

Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for ...

Staying ahead of pharma supply challenges rests on anticipatory pillars and does not require reinventing the wheel, says ...

Regene Therapeutics has received RMAT designation from the US FDA for its lead product, NouvNeu001, aimed at treating PD.

Novartis has announced that the FDA has granted a breakthrough therapy designation to ianalumab, a treatment for Sjögren’s ...

Bristol Myers Squibb (BMS) has entered into an agreement with Microsoft to advance AI-driven early lung cancer detection.

GSK's RAPT Therapeutics acquisition will strengthen the former's immunology pipeline – specifically its offerings for food ...

AstraZeneca has agreed to buy AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

As more drugs go subcutaneous, CEO of Phillips Medisize, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.